{
    "nctId": "NCT03244358",
    "briefTitle": "Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer",
    "officialTitle": "Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer:A Single Arm,Single Center,Phase II Study",
    "overallStatus": "TERMINATED",
    "conditions": "Triple Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 12,
    "primaryOutcomeMeasure": "Progression-free survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female \u2265 18 years, \u226470 years.\n* Minimum life expectancy 16 weeks\n* Histologicalconfirmation of hormone receptor negative and HER2 negative breast cancer(IHC:ER -, PR-) on primary tumour at diagnosis/on biopsy of metastasis\n* Clinical or histological confirmation of metastatic or locally advanced disease not amenable to curative surgical resection\n* ECOG 0-2 with no deterioration over previous 2 weeks Measurable disease\n* Adequate bone marrow and organ function\n* Availability of archival tumour sample or fresh biopsy Informed consent\n* Normal organ function\n\nExclusion Criteria:\n\n* Last dose chemotherapy, immunotherapy targeted therapy, biological therapy or tumour embolisation \\<21 days prior to study treatment\n* Last dose of palliative radiotherapy \\<7 days prior to study treatment\n* Rapidly progressive visceral disease not suitable for further therapy\n* Spinal cord compression or brain/meningeal metastases unless asymptomatic, treated and stable and not requiring steroids for \u2265 4 weeks study treatment\n* Major surgery (excluding placement of vascular access) within 4 weeks before study treatment\n* Evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including hepatitis B, hepatitis C and HIV\n* With the exception of alopecia, any unresolved toxicities from previous therapy greater than CTCAE grade 1 before study treatment\n* Elevated ALP in absence of bone metastasis\n* Evidence of dementia, altered mental status or any psychiatric condition that would prohibit understanding or rendering of informed consent\n* Participation in another study with investigational product during last 30 days\n* Inability or unwillingness to comply with study procedures, including inability to take regular oral medication",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}